Follow-The-Filings

Security

Acrivon Therapeutics Inc. · COMMON STOCK

Equity holders as of 2025 Q4 (each manager’s latest book)

4 owners 3 exits max 0.0% (Vanguard Group Inc.)

owners 4
max % 0.0%
tracked value $5M
qoq A 3 E 3

holders

sorted by % of portfolio · long equity only · exits show last held size

manager % port activity shares value history
Vanguard Group Inc. 2025 Q4 0.0% Add 0.00 pp 698,857 $2M hist
Two Sigma Investments, LP 2025 Q4 0.0% Exit 0.00 pp 585,069 $1M hist
Renaissance Technologies LLC 2026 Q1 stale 0.0% Add 0.00 pp 758,440 $1M hist
Marshall Wace - Marshall Wace, LLP 2026 Q1 stale 0.0% Add 0.00 pp 560,436 $779 hist
Ken Griffin - Citadel Advisors LLC exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 1,641,884 $4M hist
Israel Englander - Millennium Management LLC exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 121,524 $293 hist
Steve Cohen - Point72 Asset Management, L.P. exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 10,876 $26 hist

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue
Gross profit
Gross margin
Net income -$60.39M -$80.56M -$77.9M
Net margin

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $129.69M $181.63M $120.44M
Total non-current assets * $8.57M $14.96M $9.27M
Total assets $138.26M $196.59M $129.72M
Total current liabilities $13.3M $17.21M $15.66M
Total non-current liabilities * $3.77M $2.59M $1.54M
Total equity $121.2M $176.79M $112.52M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$42.64M -$65.67M -$63.66M
Cash from investing $50.72M -$51.77M $66.1M
Cash from financing -$1.55M $121.03M -$749,000
Net change in cash $6.52M $3.59M $1.69M

ownership over time

filing count by report period · click a bar for that quarter’s holders